Citations

Clear

6273 citation(s) found for "To, Andrew".

Open Treatment of Radial Head Fractures
Sems, S.A. , Steinmann, Scott P. , Sems, S Andrew, Adams, Julie E.

Mayo Clinic

JBJS Essential Surgical Techniques | December 13, 2017 | Volume: 7 | Issue: 4 | Pages: e35

10.2106/jbjs.st.15.00073 | PMID 30233970 Get It

Radial head fractures may commonly be treated by (1) open reduction and internal fixation (ORIF), (2) radial head excision, or (3) radial head replacement. If there is no associated elbow instability with lateral ulnar collateral ligament (LUCL) injury, the preferred approach is via a split in the extensor digitorum communis (EDC) origin. This provides a wide exposure but limits the risk of injury to the LUCL and associated instability. The radial head is fixed, excised, or replaced. Open treatment of radial head fractures begins with the following steps: (1) a laterally based incision is centered over the radiocapitellar joint, (2) the EDC is split at the midline of the radial head and elevated off the bone anteriorly and superiorly, and dissection proceeds distally, splitting the extensor origin along its fibers, and (3) the capsule is opened and the radial head fracture, identified. For ORIF, provisional fixation is then obtained with Kirschner wires and small bone reduction clamps. Headless low-profile screws are preferred if possible. If a plate is used, the dissection proceeds distally and the posterior interosseous nerve may need to be identified and protected. Definitive fixation is applied in the safe zone for implant placement (i.e., a right angle based laterally when the forearm is in a neutral position). For excision of the radial head as definitive treatment or for radial head replacement, the fragments are removed and an oscillating saw is used to remove additional radial neck or other fragments. When radial head excision is the definitive treatment, the radial neck is planed to a smooth contour that allows for placement of the prosthesis or for smooth motion without impingement at the proximal radioulnar joint. An indication for radial head replacement is suspicion of an Essex-Lopresti-type injury or demonstration of longitudinal instability of the forearm with excessive motion when a “push-pull” test is performed under fluoroscopy of the wrist while traction is applied to the radial neck. The final step of open treatment of radial head fractures, before the wound is closed in layers, consists of assessment of the range of motion and use of fluoroscopy to confirm appropriate fixation, resection, or prosthetic position. Outcomes following radial head fixation, resection, or arthroplasty for isolated radial head fractures are generally favorable. Loss of motion is particularly problematic in the pronation-supination arc in the setting of plate fixation, and patients are generally counseled that implant removal is often necessary. Loss of motion in the flexion-extension arc, particularly loss of terminal extension, may be noted. Resection of the radial head results in radiographic evidence of degenerative changes along the ulnohumeral joint, but this may be well tolerated as symptoms develop slowly, particularly in older patients. Radial head replacement results in changes in the capitellum over time, but these are usually asymptomatic.
Effects of force fields on the conformational and dynamic properties of amyloid β(1‐40) dimer explored by replica exchange molecular dynamics simulations
Watts, Charles R. , Gregory, Andrew , Frisbie, Cole P., Lovas, Sándor , Frisbie, Cole, Gregory, Andrew

Mayo Clinic

Proteins: Structure, Function, and Bioinformatics | December 13, 2017 | Volume: 86 | Issue: 3 | Pages: 279-300

10.1002/prot.25439 | PMID 29235155 Get It

Abstract The conformational space and structural ensembles of amyloid beta (Aβ) peptides and their oligomers in solution are inherently disordered and proven to be challenging to study. Optimum force field selection for molecular dynamics (MD) simulations and the biophysical relevance of results are still unknown. We compared the conformational space of the Aβ(1‐40) dimers by 300 ns replica exchange MD simulations at physiological temperature (310 K) using: the AMBER‐ff99sb‐ILDN, AMBER‐ff99sb*‐ILDN, AMBER‐ff99sb‐NMR, and CHARMM22* force fields. Statistical comparisons of simulation results to experimental data and previously published simulations utilizing the CHARMM22* and CHARMM36 force fields were performed. All force fields yield sampled ensembles of conformations with collision cross sectional areas for the dimer that are statistically significantly larger than experimental results. All force fields, with the exception of AMBER‐ff99sb‐ILDN (8.8 ± 6.4%) and CHARMM36 (2.7 ± 4.2%), tend to overestimate the α‐helical content compared to experimental CD (5.3 ± 5.2%). Using the AMBER‐ff99sb‐NMR force field resulted in the greatest degree of variance (41.3 ± 12.9%). Except for the AMBER‐ff99sb‐NMR force field, the others tended to under estimate the expected amount of β‐sheet and over estimate the amount of turn/bend/random coil conformations. All force fields, with the exception AMBER‐ff99sb‐NMR, reproduce a theoretically expected β‐sheet‐turn‐β‐sheet conformational motif, however, only the CHARMM22* and CHARMM36 force fields yield results compatible with collapse of the central and C‐terminal hydrophobic cores from residues 17‐21 and 30‐36. Although analyses of essential subspace sampling showed only minor variations between force fields, secondary structures of lowest energy conformers are different.
ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association
Alfugham, Nora, Gadoth, Avi , Lennon, Vanda A. , Komorowski, Lars , Scharf, Madeleine, Hinson, Shannon R., McKeon, Andrew , Pittock, Sean J. , Hinson, Shannon, Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | December 13, 2017 | Volume: 5 | Issue: 1 | Pages: No page available

10.1212/nxi.0000000000000418 | PMID 29379822 Get It

The prevalence of Eustachian tube dysfunction symptoms in patients with chronic rhinosinusitis
Tangbumrungtham, Navarat , Patel, Vishal S. , Thamboo, Andrew , Patel, Zara M. , Nayak, Jayakar V. , Ma, Yifei , Choby, Garret , Hwang, Peter H.

Mayo Clinic

International Forum of Allergy & Rhinology | December 11, 2017 | Volume: 8 | Issue: 5 | Pages: 620-623

10.1002/alr.22056 | PMID 29227048 Get It

Background While Eustachian tube dysfunction (ETD) is a known comorbidity of chronic rhinosinusitis (CRS), the prevalence of ETD symptoms in the CRS population is poorly understood. We sought to determine the cross‐sectional prevalence of ETD in patients with CRS using the validated Eustachian Tube Dysfunction Questionnaire (ETDQ‐7) and to correlate ETDQ‐7 scores with 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores, endoscopy scores, and computed tomography (CT) scores. Methods A total of 101 patients with confirmed CRS completed the ETDQ‐7 and SNOT‐22 at their initial visit to our rhinology clinic. Lund‐Mackay CT and Lund‐Kennedy endoscopy scores were also obtained. Spearman's correlation coefficient (ρ) was calculated. Results Among the 101 patients, 49 patients (48.5%) had an ETDQ‐7 score of ≥14.5, signifying clinically significant ETD. The mean ± standard deviation (SD) ETDQ‐7 score of the entire cohort was 17.8 ± 10.1. There was a moderately strong correlation between ETDQ‐7 and the SNOT‐22 ear subdomain (ρ = 0.691, p < 0.001). The correlation coefficient between ETDQ‐7 and total SNOT‐22 scores was ρ = 0.491 ( p < 0.001), indicating moderate correlation. ETDQ‐7 scores were poorly correlated to objective measures of sinonasal disease, including Lund‐Mackay CT score (ρ = −0.055, p = 0.594) and Lund‐Kennedy endoscopy score (ρ = −0.099, p = 0.334). Conclusion Symptoms of ETD are highly prevalent among patients with CRS as documented by patient‐reported outcome measures. The correlation between ETDQ‐7 scores and SNOT‐22 ear subdomain scores is moderately strong, while the correlation between ETDQ‐7 scores and SNOT‐22 scores is moderate. ETD severity does not correlate with CT score or nasal endoscopy score.
Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history
Perez, Carla Fiorella Murillo, Goet, Jorn , Lammers, Willem J. , Gulamhusein, Aliya , Buuren, Henk R. van , Ponsioen, Cyriel Y. , Carbone, Marco , Mayo, Marlyn J. , Floreani, Annarosa , Parés, Albert , Nevens, Frederik , Bruns, Tony , Thorburn, Douglas , Lindor, Keith D. , Zachou, Kalliopi , Poupon, Raoul, Verhelst, Xavier , Janssen, Harry L.A. , Group, on behalf of the GLOBAL PBC Study, Goet, Jorn C , Bruns, Tony , Carbone, Marco , Verhelst, Xavier , Mason, Andrew L. , Corpechot, Christophe , Invernizzi, Pietro , Battezzati, Pier Maria , Kowdley, Kris V. , Dalekos, George Ν. , Hirschfield, Gideon M. , LaRusso, Nicholas F. , Trivedi, Palak Jitendrakumar , Hansen, Bettina E. , Group, on behalf of the GLOBAL PBC Study

Mayo Clinic

Hepatology | December 9, 2017 | Volume: 67 | Issue: 5 | Pages: 1920-1930

10.1002/hep.29717 | PMID 29220537 Get It

Changes over time in the presenting features and clinical course of patients with primary biliary cholangitis are poorly described. We sought to describe temporal trends in patient and disease characteristics over a 44‐year period across a large international primary biliary cholangitis cohort of 4,805 patients diagnosed between 1970 and 2014, from 17 centers across Europe and North America. Patients were divided into five cohorts according to their year of diagnosis: 1970‐1979 (n = 143), 1980‐1989 (n = 858), 1990‐1999 (n = 1,754), 2000‐2009 (n = 1,815), and ≥2010 (n = 235). Age at diagnosis, disease stage, response to ursodeoxycholic acid, and clinical outcomes were compared. Mean age at diagnosis increased incrementally by 2‐3 years per decade from 46.9 ± 10.1 years in the 1970s to 57.0 ± 12.1 years from 2010 onward (P < 0.001). The female to male ratio (9:1) and antimitochondrial antibody positivity (90%) were not significantly variable. The proportion of patients presenting with mild biochemical disease (according to Rotterdam staging) increased from 41.3% in the 1970s to 72.2% in the 1990s (P < 0.001) and remained relatively stable thereafter. Patients with a mild histological stage at diagnosis increased from 60.4% (1970‐1989) to 76.5% (1990‐2014) (P < 0.001). Correspondingly, response to ursodeoxycholic acid according to Paris‐I criteria increased; 51.7% in the 1970s and 70.5% in the 1990s (P < 0.001). Recent decades were also characterized by lower decompensation rates (18.5% in the 1970s to 5.8% in the 2000s, P < 0.001) and higher 10‐year transplant‐free survival (48.4%, 68.7%, 79.7%, and 80.1% for each respective cohort; P < 0.001). Conclusion: In recent decades, a pattern of primary biliary cholangitis presentation consistent with an older age at diagnosis alongside reduced disease severity has been noted; the observed trends may be explained by an increase in routine testing of liver function and/or a changing environmental trigger. (Hepatology 2018;67:1920‐1930).
Long-term successful closure of a percutaneous intragastric trocar tract with crossing full-thickness sutures in a porcine model
Storm, Andrew C. , Aihara, Hiroyuki , Skinner, Matthew J. , Ryou, Marvin , Thompson, Christopher , Storm, Andrew C , Thompson, Christopher

Mayo Clinic

Endoscopy | December 8, 2017 | Volume: 50 | Issue: 06 | Pages: 626-630

10.1055/s-0043-122498 | PMID 29220858 Get It

Abstract Background and study aims A novel intragastric trocar placed using a percutaneous endoscopic gastrostomy technique enables the use of laparoscopic tools and procedures, including tissue stapling, cutting, suturing, and retraction. The aim of this porcine study was to determine long-term success of crossing full-thickness sutures in closure of the tract upon trocar withdrawal. Methods 10 trocars were placed in 5 animals. Each animal underwent a standardized tissue resection using a 5-mm stapler under gastroscopic guidance, and two full-thickness, absorbable, crossing sutures were used to close the trocar tracts. The animals were monitored for 35 days and then euthanized for necropsy. Results All five animals survived without sign of infection or distress. Nine of the 10 trocar sites healed completely without any adverse findings. A single site developed a gastrocutaneous fistula. On necropsy, there was no evidence of intra-abdominal infection or abscess. Conclusions Full-thickness crossing sutures appeared to be effective in long-term closure of an intragastric trocar tract. Given the ease of placement and success of this simple closure method, this device may prove clinically useful to the endoscopist performing complex procedures in the endoscopy suite.
Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases
Dubey, Divyanshu , Lennon, Vanda A. , Gadoth, Avi , Pittock, Sean J. , Schmeling, John E., McKeon, Andrew , Klein, Christopher J. , Pittock, S J , Klein, Christopher J , McKeon, Andrew , Dubey, Divyanshu , Flanagan, Eoin P.

Mayo Clinic

Neurology | December 8, 2017 | Volume: 90 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000004803 | PMID 29222126 Get It

Irrigation and Debridement with Component Retention for Acute Infection After Hip Arthroplasty
Bryan, Andrew J., Sanders, Thomas L. , Fitzgerald, Steven F., Hanssen, Arlen D. , Berry, Daniel J. , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

Journal of Bone and Joint Surgery | December 6, 2017 | Volume: 99 | Issue: 23 | Pages: 2011-2018

10.2106/jbjs.16.01103 | PMID 29206791 Get It

Background: There are conflicting data on the results of irrigation and debridement with component retention in patients with acute periprosthetic hip infections. The goals of this study were to examine contemporary results of irrigation and debridement with component retention for acute infection after primary hip arthroplasty and to identify host, organism, antibiotic, or implant factors that predict success or failure. Methods: Ninety hips (57 total hip arthroplasties and 33 hemiarthroplasties) were diagnosed with acute periprosthetic hip infection (using strict criteria) and were treated with irrigation and debridement and component retention between 2000 and 2012. The mean follow-up was 6 years. Patients were stratified on the basis of McPherson criteria. Hips were managed with irrigation and debridement and retention of well-fixed implants with modular head and liner exchange (70%) or irrigation and debridement alone (30%). Seventy-seven percent of patients were treated with chronic antibiotic suppression. Failure was defined as failure to eradicate infection, characterized by a wound fistula, drainage, intolerable pain, or infection recurrence caused by the same organism strain; subsequent removal of any component for infection; unplanned second wound debridement for ongoing deep infection; and/or occurrence of periprosthetic joint infection-related mortality. Results: Treatment failure occurred in 17% (15 of 90 hips), with component removal secondary to recurrent infection in 10% (9 of 90 hips). Treatment failure occurred in 15% (10 of 66 hips) after early postoperative infection and 21% (5 of 24 hips) after acute hematogenous infection (p = 0.7). Patients with McPherson host grade A had a treatment failure rate of 8%, compared with 16% (p = 0.04) in host grade B and 44% in host grade C (p = 0.006). Most treatment failures (12 of 15 failures) occurred within the initial 6 weeks of treatment; failures subsequent to 6 weeks occurred in 3% of those treated with chronic antibiotic suppression compared with 11% of those who were not treated with suppression (hazard ratio, 4.0; p = 0.3). Conclusions: The success rate was higher in this contemporary series than in many previous series. Systemic host grade A was predictive of treatment success. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
A path to understanding autoimmune GFAP astrocytopathy
Ζεκερίδου, Αναστασία , McKeon, Andrew , Flanagan, E P , McKeon, Andrew , Flanagan, Eoin P.

Mayo Clinic

European Journal of Neurology | November 29, 2017 | Volume: 25 | Issue: 3 | Pages: 421-422

10.1111/ene.13527 | PMID 29193488 Get It

Click here to view the accompanying paper in this volume.
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, Milind , Lowery, Maeve A. , Shroff, Rachna T. , Weiss, Karl Heinz , Springfeld, Christoph , Ramanathan, Ramesh K., Sadeghi, Saeed , Macarulla, Teresa , Kelley, Robin Kate , Borbath, Ivan , Choo, Su Pin , Oh, Do‐Youn , Reungwetwattana, Thanyanan , Yeh, Kun‐Huei , Ciombor, Kristen K. , Patel, Anuradha , Porter, Dale, Isaacs, Randi , Zhu, Andrew X. , Bekaii‐Saab, Tanios , Lowery, Maeve, Goyal, Lipika , El-Khoueiry, Anthony, Chen, Li‐Tzong , van Cutsem, Eric, Ciombor, Kristen, Sen, Suman, Abou-Alfa, Ghassan K, Bekaii-Saab, Tanios S , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Philip, Philip A. , Cutsem, Eric Van , Finn, Richard S. , Sen, Suman , Abou‐Alfa, Ghassan K. , Macarulla, Teresa

Mayo Clinic

Journal of Clinical Oncology | November 28, 2017 | Volume: 36 | Issue: 3 | Pages: 276-282

10.1200/jco.2017.75.5009 | PMID 29182496 Get It

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. Patients received BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles). The primary end point was investigator-assessed overall response rate. Results Sixty-one patients (35 women; median age, 57 years) with FGFR2 fusion (n = 48), mutation (n = 8), or amplification (n = 3) participated. At the prespecified data cutoff (June 30, 2016), 50 patients had discontinued treatment. All responsive tumors contained FGFR2 fusions. The overall response rate was 14.8% (18.8% FGFR2 fusions only), disease control rate was 75.4% (83.3% FGFR2 fusions only), and estimated median progression-free survival was 5.8 months (95% CI, 4.3 to 7.6 months). Adverse events included hyperphosphatemia (72.1% all grade), fatigue (36.1%), stomatitis (29.5%), and alopecia (26.2%). Grade 3 or 4 treatment-related adverse events occurred in 25 patients (41%) and included hyperphosphatemia (16.4%), stomatitis (6.6%), and palmar-plantar erythrodysesthesia (4.9%). Conclusion BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. This promising antitumor activity supports continued development of BGJ398 in this highly selected patient population.